NSE: AUROPHARMA | BSE: 524804

Turnaround Potential

Download real time

1314.20 6.40 (0.49%)

New 52W High in past week

2.0M NSE+BSE Volume

NSE 27 Mar, 2026 3:31 PM (IST)

76,328.9

Market Cap

High in industry

Beta 1Year

Low volatility

Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Search Inside the pdf :

Aurobindo Pharma Ltd.

23 Mar 2026

1314.20

0.49%

Backward & forward integration unlocking PenG value chain

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

Under the Production-Linked Incentive (PLI) scheme, ARBP constructed the PENG and 6-APA plants within a record three-year period and ramped up production following the start of the PEN-G plant in Jul’25.

Motilal Oswal increased Buy price target of Aurobindo Pharma Ltd. to 1500.0 on 23 Mar, 2026.

Aurobindo Pharma Ltd.

15 Feb 2026

1314.20

0.49%

Aurobindo Pharma Ltd.

Buy: Aurobindo Pharma Ltd.

Target

ICICI Direct

The performance was more or less in sync with the overall FY26 management guidance with flattish US growth (wanning gRevlimid traction and pending approvals from Eugia III), overall single-digit growth, and EBITDA margins around ~21% (came in slightly lower though). European growth has been consistently strong over the last few quarters. Going forward, while sustainability of the EBITDA margins will be the key monitorable as the company plans to expand the R&D bandwidth and diversify into more complex models such as biosimilars, the GPMs are...

Aurobindo Pharma Ltd. has an average target of 1345.11 from 9 brokers.

Aurobindo Pharma Ltd.

11 Feb 2026

1314.20

0.49%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Axis Direct

We maintain our BUY recommendation on the stock with a TP of Rs 1,345/share.

Aurobindo Pharma Ltd. is trading above all available SMAs

Aurobindo Pharma Ltd.

10 Feb 2026

1314.20

0.49%

Aurobindo Pharma (BUY): In-line result; Europe to be the key growth driver

Buy: Aurobindo Pharma Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were 1%/-0.4%/4% below our estimates. Adjusting for a one-time expense of Rs 653 mn, APAT was 2.5% above estimates

Aurobindo Pharma Ltd. has an average target of 1345.11 from 9 brokers.

Aurobindo Pharma Ltd.

10 Feb 2026

1314.20

0.49%

EU + ARV drive earnings; gross margin boost sustains

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

Aurobindo Pharma (ARBP) posted better-than-expected revenue/EBITDA for the quarter, driven by healthy growth momentum in the EU and ARV segments and currency benefits.

Aurobindo Pharma Ltd. has an average target of 1345.11 from 9 brokers.

Aurobindo Pharma Ltd.

29 Jan 2026, 12:00AM

1314.20

0.49%

Pen-G policy tailwind kicks in

Buy: Aurobindo Pharma Ltd.

Motilal Oswal

Minimum import duties on Pen-g, 6-APA, and amoxicillin sales are expected to boost Aurobindo Pharma’s (ARBP) overall performance over the next one year. We build in an INR5.5b-INR6.6b EBITDA, including PLI income, from this project over the next 12M.

Aurobindo Pharma has gained 20.57% in the last 6 Months

Aurobindo Pharma Ltd.

03 Dec 2025

1314.20

0.49%

Broad-based growth momentum building up

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

With considerable investment (INR35b) done till date by Aurobindo Pharma (ARBP) in the Pen-G/6-APA project and support from the government under the PLI scheme, ARBP is scaling up the production to enhance self-sufficiency of India in bulk drugs/intermediates to be used for Beta-Lactum antibiotics.

Aurobindo Pharma Ltd. is trading above all available SMAs

Aurobindo Pharma Ltd.

10 Nov 2025

1314.20

0.49%

Aurobindo Pharma Ltd.

Buy: Aurobindo Pharma Ltd.

Target

ICICI Direct

Q2FY26- Muted numbers on expected lines Revenues grew ~6% YoY to 8286 crore due to softness in the US (44% of the revenues) which grew 3% to 3638 crore. Europe (30% of the revenues) grew 18% to 2480 crore and ARV (~4% of the revenues) grew 68% to 325 crore. Growth Markets (~10% of the revenues) grew ~9% YoY to 882 crore (including India formulations). APIs de-grew at 17% YoY to 961 crores. EBITDA grew 7% YoY to 1678 crore while EBITDA margins increased 16 bps to 20.3%. EBITDA de-growth was mainly driven by increase in employee expenses....

Aurobindo Pharma Ltd. is trading above all available SMAs

Aurobindo Pharma Ltd.

10 Nov 2025

1314.20

0.49%

Outlook supported by recovery in Injectables, ramp-up of Pen-G and biosimilars

Accumulate: Aurobindo Pharma Ltd.

Target

Deven Choksey

Aurobindo Pharma delivered a steady quarter, with revenue growth driven mainly by formulations, particularly Europe and a stable US base supported by new product launches.